Cell capable of expressing exogenous GITR ligand
First Claim
1. A pharmaceutical composition comprising an excipient and an immune cell capable of expressing an exogenous Glucocorticoid-Induced Tumor necrosis factor Receptor Ligand (GITRL) derivative, wherein said GITRL derivative is a fusion protein consisting of amino acids 50-177 of SEQ ID NO:
- 6 fused to an Fc fragment of an immunoglobulin, wherein the composition comprises 1×
103 to 1×
1011 cells/mL of said immune cell.
2 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject.
-
Citations
8 Claims
-
1. A pharmaceutical composition comprising an excipient and an immune cell capable of expressing an exogenous Glucocorticoid-Induced Tumor necrosis factor Receptor Ligand (GITRL) derivative, wherein said GITRL derivative is a fusion protein consisting of amino acids 50-177 of SEQ ID NO:
- 6 fused to an Fc fragment of an immunoglobulin, wherein the composition comprises 1×
103 to 1×
1011 cells/mL of said immune cell. - View Dependent Claims (2, 3, 4)
- 6 fused to an Fc fragment of an immunoglobulin, wherein the composition comprises 1×
-
5. A pharmaceutical composition comprising an excipient and an inactivated tumor cell capable of expressing an exogenous Glucocorticoid-Induced Tumor necrosis factor Receptor Ligand (GITRL) derivative, wherein said GITRL derivative is a fusion protein consisting of amino acids 50-177 of SEQ ID NO:
- 6 fused to an Fc fragment of an immunoglobulin, wherein the composition comprises 1×
103 to 1×
1011 cells/mL of said inactivated tumor cell. - View Dependent Claims (6, 7, 8)
- 6 fused to an Fc fragment of an immunoglobulin, wherein the composition comprises 1×
Specification